On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE trial in the second quarter Positive topline ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

or del-zota for short — formerly called AOC 1044 — was found to safely increase levels of dystrophin production to 25% of normal in people with Duchenne muscular dystrophy (DMD), according to new data ...

The company announced positive topline data from its Phase 1/2 EXPLORE44 trial for del-zota, a potential treatment for Duchenne muscular dystrophy, showing statistically significant improvements in ...